Russian fund signs Italy deal for production of Sputnik vaccine

The company will be able to start production in July and produce 10 million doses by year end.

Russian fund signs Italy deal for production of Sputnik vaccine

The Russian Direct Investment Fund has struck a deal to produce the Russian Sputnik V vaccine in Italy, the Italian-Russian Chamber of Commerce announced Monday.

The Italian-Swiss firm Adienne Pharma & Biotech has signed a strategic agreement with RDIF — a sovereign wealth fund that promotes the vaccine abroad — to manufacture the shot in Italy in its first European production deal, according to the trade body.

The company will be able to start production in July and produce 10 million doses by year end. Production will take place in a manufacturing site near Milan, in Lombardy.

If the vaccine gets approval of the European Medicines Agency, the doses will be reserved exclusively for the Italian market, according to a spokesperson for the chamber of commerce. Otherwise, the jabs will be exported to countries that have approved the vaccine.

The EMA started a rolling review of the vaccine last week. Hungary and Slovakia have started to receive doses of the vaccine without waiting for the EMA’s sign-off.

The Italian-Russian Chamber of Commerce said that the agreement resulted from a series of meetings it organized starting in October, as it sought to find a partner to produce doses of the Russian jab.

According to newspaper Il Messaggero, Italian Health Minister Roberto Speranza has said he’s not opposed to using Sputnik as long as it gets the EMA’s recommendation.

This article is part of POLITICO’s premium policy service: Pro Health Care. From drug pricing, EMA, vaccines, pharma and more, our specialized journalists keep you on top of the topics driving the health care policy agenda. Email for a complimentary trial. 

Source : Politico EU More